Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar (octreotide acetate) is a protein pharmaceutical. Octreotide acetate was first approved as Bynfezia pen on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. Sandostatin's patents are valid until 2036-02-03 (FDA).
|Trade Name||Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar|
|Common Name||Octreotide acetate|
|Indication||acromegaly, adenoma, diarrhea, pancreatic neoplasms, pituitary neoplasms|
|Drug Class||Peptides: inhibition of growth hormone release|